Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC

被引：0

作者：

Liu, L. ^{[1
]}

Liu, J. ^{[2
]}

Liu, Y. ^{[1
]}

Yu, X. ^{[2
]}

Li, S. ^{[1
]}

Li, B. ^{[1
]}

Guo, S. ^{[2
]}

Zhang, Y. ^{[3
]}

Wang, Y. ^{[1
]}

Zheng, T. ^{[1
]}

Han, W. ^{[1
]}

Xie, Y. ^{[2
]}

Zhou, L. ^{[2
]}

Zhang, J. ^{[2
]}

Zhao, Y. ^{[2
]}

Li, Y. ^{[2
]}

Hu, Y. ^{[1
]}

Wang, J. ^{[1
]}

Cao, H. ^{[1
]}

机构：

[1] Shandong Univ, Qilu Hosp, Jinan, Peoples R China

[2] Shandong Publ Hlth Clin Ctr, Jinan, Peoples R China

[3] Shandong Canc Hosp, Jinan, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Envafolimab; sq-NSCLC; First-line;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4.11E.06

引用

页码：S397 / S397

页数：1

共 50 条

[31] Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
Zhao, J.
Wang, Z.
Ma, Z.
Cui, J.
Shu, Y.
Liu, Z.
Cheng, Y.
Leaw, S.
Li, J.
Xia, F.
Wang, J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S540 - S540
[32] The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma
Chen, Ming-Qiu
Chen, Cheng
Lu, Hai-Jie
Xu, Ben-Hua
JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1749 - 1755
[33] Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?
Zheng, Yulong
Xu, Nong
Zhou, Jianying
LANCET ONCOLOGY, 2013, 14 (11): : E438 - E438
[34] Influence of baseline inflammatory markers on the response to first-line chemotherapy in advanced NSCLC
MacDonald, N.
Kasymjanova, G.
Agulnik, J. S.
Pepe, C.
Kreisman, H.
Cohen, V.
Sharma, R.
Gagnon, B.
Small, D.
EJC SUPPLEMENTS, 2007, 5 (04): : 385 - 385
[35] Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin first-line therapy for advanced non-small cell lung cancer
Huang, H.
Fu, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1031 - S1031
[36] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
Rihua Cheng
Zhen Zhou
Qiao Liu
Advances in Therapy, 2023, 40 : 4298 - 4309
[37] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
Cheng, Rihua
Zhou, Zhen
Liu, Qiao
ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
[38] Immunotherapy in the First-Line Setting of Advanced NSCLC
Herbst, Roy
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S107 - S108
[39] Bevacizumab in the first-line therapy of advanced NSCLC
Hasenoehrl, Norbert
WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
[40] First-line single agent treatment with gefitinib in patients with advanced NSCLC
Brossart, Peter
STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (08) : 490 - 491

← 1 2 3 4 5 →